Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel

Blood (2022) 140 (Supplement 1): 12973–12975.

https://doi.org/10.1182/blood-2022-165289

Published: 2022

Journal Articles

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

John F. DiPersio, MD PhD, Jonathan Hoggatt, PhD, Steven Devine, MD, Lukasz Biernat, MD, Haley Howell, BS, BA, Veit Schmelmer, PhD, Jason R. Neale, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Glen D. Raffel, MD PhD, Patrick C. Falahee, PhD, Dwight M. Morrow, PhD, John C. Davis, Jr., MD MPH, MS

Blood (2019) 134 (Supplement_1): 1961.

https://doi.org/10.1182/blood-2019-127523

Published: 2019

Journal Articles

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Heather Stefanski, MD PhD, Claudio G Brunstein, MD PhD, David H. McKenna, MD, Darin Sumstad, MLS, Jeffrey S. Miller, MD, Bruce R. Blazar, MD, Todd E. DeFor, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Glen D. Raffel, MD PhD, John C. Davis, Jr., MD MPH, MS, John E. Wagner, MD

Blood (2019) 134 (Supplement_1): 804.

https://doi.org/10.1182/blood-2019-122329

Published: 2019

Journal Articles

Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34 + Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD)

Paul Orchard, MD, Glen D. Raffel, MD, Carolyn H Condon, MPH, Catherine A Monaghan, Demetra Vernet, Suzanne Tracey Sheirr, Jennifer Braun, RN BSN, Ryan Shanley, M.S, Troy C Lund, MD MS, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, John C Davis, MD MPH, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2018-99-115102

Published: 2018

Journal Articles

High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia

Neeraj Y Saini, MD, Jan Cerny, MD PhD, Vanessa Furtado, MD, Angela Desmond, Zheng Zhou, Glen D. Raffel, MD, Imran Puthawala, Jayde Bednarik, PharmD, Lindsey Shanahan, Patricia Minehart Miron, PhD, Bruce Woda, MD, Muthalagu Ramanathan, MD, Rajneesh Nath, MD

Blood (2018) 132 (Supplement 1): 1430.

https://doi.org/10.1182/blood-2018-99-116857

Published: 2018

Journal Articles

Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform

Sakiko Suzuki, MD, Ronny R Racine, PhD BS, Nathan A Manalo, MS, Neeraj Saini, MD, Cliff Odour, Michael Moazami, MS, Jeffrey A Bailey, MD PhD, Jonathan K Watts, PhD, Glen D. Raffel, MD PhD

Blood (2017) 130 (Supplement 1): 383.

https://doi.org/10.1182/blood.V130.Suppl_1.383.383

Published: 2017

Journal Articles

Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

Rajneesh Nath, MD, Jan Cerny, MD PhD, Muthalagu Ramanathan, MD, Zheng Zhou, MD PhD, Neng Yu, MD, Glen D Raffel, MD PhD, Jayde Bednarik, PharmD

Blood (2016) 128 (22): 5875.

https://doi.org/10.1182/blood.V128.22.5875.5875

Published: 2016

Journal Articles

Ott1(Rbm15) Regulates p53 Levels during Oncogenic and Proliferative Stress

Sakiko Suzuki, MD, Nathan A Manalo, B.A. M.A., Glen D Raffel, MD PhD

Blood (2015) 126 (23): 1189.

https://doi.org/10.1182/blood.V126.23.1189.1189

Published: 2015

Journal Articles

Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl

Nan Xiao, Suparna Laha, Shankar P. Das, Kayla Morlock, Jonathan L. Jesneck, Glen D. Raffel

Blood (2015) 125 (6): 941–948.

https://doi.org/10.1182/blood-2014-08-593392

Published: 2015

Journal Articles

Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)

Rajneesh Nath, MD, Muthalagu Ramanathan, MD, Jan Cerny, MD PhD, Zheng Zhou, MD PhD, Glen D Raffel, MD PhD, Jayde Bednarik, Pharm D, Neng Yu, MD, Laura J Petrillo-Deluca, PA-C, Zeina Al-Mansour, MD, Zankar Desai

Blood (2014) 124 (21): 1152.

https://doi.org/10.1182/blood.V124.21.1152.1152

Published: 2014

Journal Articles

High Dose Cyclophosphamide (HDCy) Post Stem Cell Transplant (SCT) Following High Dose Melphalan (HDMel) Based Conditioning As a Dual Strategy For Chemotherapy Dose Intensity and Graft Versus Host Disease (gvhd) Prophylaxis In Matched and Mismatched allogeneic (allo) SCT

Rajneesh Nath, MD, Jan Cerny, MD, Ph.D, Muthalagu Ramanathan, MD, Glen D Raffel, M.D, Ph.D., Jayde Bednarik, Pharm D, Neng Yu, MD, Zankar Desai, Lindsey Shanahan, PA-C, Natasha Fortier, PA-C, Mridula George, MD, Aimee Kroll-Desrosiers, MS

Blood (2013) 122 (21): 4554.

https://doi.org/10.1182/blood.V122.21.4554.4554

Published: 2013

Journal Articles

Ott1(Rbm15) Regulates Thpo Response In HSCs Through Epigenetic Modifications Directing Alternative Splicing Of C-Mpl

Nan Xiao, Ph.D., Kayla Morlock, Jonathan L Jesneck, PhD, Glen D Raffel, M.D, Ph.D.

Blood (2013) 122 (21): 222.

https://doi.org/10.1182/blood.V122.21.222.222

Published: 2013

Journal Articles

Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress

Nan Xiao, Kaushal Jani, Kelly Morgan, Rachel Okabe, Dana E. Cullen, Jonathan L. Jesneck, Glen D. Raffel

Blood (2012) 119 (21): 4898–4907.

https://doi.org/10.1182/blood-2012-01-403089

Published: 2012

Includes: Supplemental data

Journal Articles

Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT),

Jan Cerny, MD, PhD, Lesley Woods, MD, Hongbo Yu, MD, PhD, Muthalagu Ramanathan, MD, Glen D Raffel, M.D, Ph.D., William V Walsh, MD, Laura J Petrillo-Deluca, PA-C, Natasha M Tarrasky, PA-C, Elizabeth O'Rourke, NP, Jayde L Bednarik, PharmD, Bruce Woda, MD, Lloyd Hutchinson, PhD, Aimee Kroll, MS, Bruce Barton, PhD, Alan G. Rosmarin, MD, Rajneesh Nath, MD

Blood (2011) 118 (21): 3560.

https://doi.org/10.1182/blood.V118.21.3560.3560

Published: 2011

Journal Articles

Ott1 ( Rbm15 )-Deficient Hematopoietic Stem Cells Are Unable to Maintain Quiescence During Replicative Stress and Display Features of Premature Aging,

Nan Xiao, Ph.D., Kaushal Jani, B.A., Jonathan L Jesneck, PhD, Glen D Raffel, M.D, Ph.D.

Blood (2011) 118 (21): 3433.

https://doi.org/10.1182/blood.V118.21.3433.3433

Published: 2011

Journal Articles

High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML)

Muthalagu Ramanathan, MD, Zheng Zhou, MD, Jan Cerny, MD, PhD, Glen D Raffel, M.D, Ph.D., Laura Petrillo-Deluca, William Vincent Walsh, MD, Venu Bathini, MD, Micheal Vail, Karen Smethers, Bruce Woda, MD, Patricia Miron, MD, Alan G. Rosmarin, MD, Rajneesh Nath, MD

Blood (2010) 116 (21): 3290.

https://doi.org/10.1182/blood.V116.21.3290.3290

Published: 2010

Journal Articles

FLT3ITD Expression Confers the Leukemogenic Properties of Growth Factor Independence and Enhanced Self-Renewal to Yolk Sac Progenitors.

Nan Xiao, Ph.D., Kaushal Jani, B.A., Yuxia Yang, Ph.D., Glen D Raffel, M.D, Ph.D.

Blood (2010) 116 (21): 1576.

https://doi.org/10.1182/blood.V116.21.1576.1576

Published: 2010

Journal Articles

Vascular Branching Morphogenesis of the Placenta Requires Expression of Ott1(Rbm15) in the Trophoblast Compartment.

Glen D. Raffel, MD, PhD, Gerry C Chu, Dana E. Cullen, Roderick T Bronson, DVM, Olivier A Bernard, D. Gary Gilliland

Blood (2008) 112 (11): 1895.

https://doi.org/10.1182/blood.V112.11.1895.1895

Published: 2008

NARROW

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34 + Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD)

High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia

Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform

Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

Ott1(Rbm15) Regulates p53 Levels during Oncogenic and Proliferative Stress

Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl

Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)

High Dose Cyclophosphamide (HDCy) Post Stem Cell Transplant (SCT) Following High Dose Melphalan (HDMel) Based Conditioning As a Dual Strategy For Chemotherapy Dose Intensity and Graft Versus Host Disease (gvhd) Prophylaxis In Matched and Mismatched allogeneic (allo) SCT

Ott1(Rbm15) Regulates Thpo Response In HSCs Through Epigenetic Modifications Directing Alternative Splicing Of C-Mpl

Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress

Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT),

Ott1 ( Rbm15 )-Deficient Hematopoietic Stem Cells Are Unable to Maintain Quiescence During Replicative Stress and Display Features of Premature Aging,

High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML)

FLT3ITD Expression Confers the Leukemogenic Properties of Growth Factor Independence and Enhanced Self-Renewal to Yolk Sac Progenitors.

Vascular Branching Morphogenesis of the Placenta Requires Expression of Ott1(Rbm15) in the Trophoblast Compartment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only